Despite many advances in pharmacotherapy over the past half centurye, only a fraction of
patients with Major Depressive Disorder (MDD) can achieve remission after the first or …

Objective: Major depressive disorder (MDD) affects about 10–15% of the general population
in a lifetime. A considerable number of patients fail to achieve full symptom remission …

Objective: To comparatively analyze the efficacy, acceptability, and tolerability of various
augmentation agents in adult patients with treatment-resistant depression. Data Sources: An …

Objective: To examine the available scientific evidence for answers to clinically relevant
questions on the effectiveness and tolerability of antidepressant drugs (ADs) for the long …

The aim of the present study was to critically appraise current conceptual approaches;
demographic, neurobiological and clinical correlates; and management strategies of …

Clinical trials indicate that over 50% of depressed patients show an inadequate response to
antidepressant therapy, and that incomplete recovery from major depressive disorder (MDD) …

This review from the RTI International–University of North Carolina at Chapel Hill Evidence-
based Practice Center (EPC) provides a comprehensive summary of the available data …

Objective: Selective serotonin reuptake inhibitors (SSRIs) are frequently used as a first
antidepressant for major depressive disorder but have response rates of 50% to 60% in …

Treatment resistant depression (TRD) is associated with poor outcomes, but a consensus is
lacking in the literature regarding which compound represents the best pharmacological …

Background: The large majority of depressed patients fail to remit on the first antidepressant
prescribed. These patients with residual symptoms have higher relapse rates and poorer …